David Beauvais

1.5k total citations
39 papers, 329 citations indexed

About

David Beauvais is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, David Beauvais has authored 39 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in David Beauvais's work include CAR-T cell therapy research (13 papers), Acute Myeloid Leukemia Research (6 papers) and Hematopoietic Stem Cell Transplantation (5 papers). David Beauvais is often cited by papers focused on CAR-T cell therapy research (13 papers), Acute Myeloid Leukemia Research (6 papers) and Hematopoietic Stem Cell Transplantation (5 papers). David Beauvais collaborates with scholars based in France, Switzerland and Canada. David Beauvais's co-authors include Ibrahim Yakoub‐Agha, Pauline Varlet, Thierry Façon, Myriam Labalette, Julie Demaret, Jacques Trauet, Suman Mitra, Charles Herbaux, Franck Morschhauser and Salomon Manier and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Clinical Cancer Research.

In The Last Decade

David Beauvais

31 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Beauvais France 10 168 97 95 48 42 39 329
Hamza Hashmi United States 11 274 1.6× 198 2.0× 177 1.9× 22 0.5× 44 1.0× 102 476
Santiago Thibaud United States 9 148 0.9× 129 1.3× 55 0.6× 34 0.7× 35 0.8× 33 331
Kirsten M Boughan United States 7 146 0.9× 93 1.0× 54 0.6× 11 0.2× 24 0.6× 35 263
Odelia Amit Israel 13 278 1.7× 167 1.7× 92 1.0× 44 0.9× 44 1.0× 39 525
Caroline L. Furness United Kingdom 12 115 0.7× 65 0.7× 54 0.6× 32 0.7× 37 0.9× 19 317
Tomoyasu Jo Japan 9 102 0.6× 113 1.2× 44 0.5× 46 1.0× 26 0.6× 37 268
Ben Carpenter United Kingdom 11 160 1.0× 77 0.8× 30 0.3× 44 0.9× 22 0.5× 28 320
Rafic Farah United States 11 254 1.5× 102 1.1× 64 0.7× 31 0.6× 33 0.8× 31 408
Agrima Mian United States 8 151 0.9× 22 0.2× 47 0.5× 21 0.4× 15 0.4× 36 248
Alberto Mussetti Spain 13 251 1.5× 196 2.0× 96 1.0× 17 0.4× 43 1.0× 51 435

Countries citing papers authored by David Beauvais

Since Specialization
Citations

This map shows the geographic impact of David Beauvais's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Beauvais with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Beauvais more than expected).

Fields of papers citing papers by David Beauvais

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Beauvais. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Beauvais. The network helps show where David Beauvais may publish in the future.

Co-authorship network of co-authors of David Beauvais

This figure shows the co-authorship network connecting the top 25 collaborators of David Beauvais. A scholar is included among the top collaborators of David Beauvais based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Beauvais. David Beauvais is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ferrant, Emmanuelle, Rémy Duléry, David Beauvais, et al.. (2025). Anti‐CD19 CAR T‐cell therapy for patients with Richter transformation: A LYSA study from the DESCAR‐T registry. British Journal of Haematology. 207(3). 1143–1147.
2.
Chevret, Sylvie, Xavier Poiré, Magalie Joris, et al.. (2024). Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Bone Marrow Transplantation. 59(7). 965–973.
3.
Magro, Léonardo, David Beauvais, Micha Srour, et al.. (2023). High frequency of cutaneous eruptions within the first year after allogeneic hematopoietic stem cell transplantation. SHILAP Revista de lepidopterología. 2(3). 456–464. 1 indexed citations
4.
Fréalle, Émilie, et al.. (2022). A case of subacute bowel obstruction revealing slowly-evolutive gastro-intestinal mucormycosis following allogeneic hematopoietic cell transplantation. Journal de Mycologie Médicale. 32(4). 101312–101312. 3 indexed citations
5.
Yakoub‐Agha, Ibrahim, Nassima Ramdane, Micha Srour, et al.. (2022). Impact of Defibrotide in the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation. Annals of Pharmacotherapy. 56(9). 1007–1015. 4 indexed citations
6.
Drumez, Élodie, Valérie Coiteux, Léonardo Magro, et al.. (2022). Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology. 101(6). 1321–1331. 6 indexed citations
7.
Faure, Emmanuel, Hélène Behal, Micha Srour, et al.. (2022). The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients. Blood Advances. 7(5). 856–865. 9 indexed citations
8.
9.
Beauvais, David, Anne‐Sophie Moreau, Pauline Varlet, et al.. (2022). A potential role of preexisting inflammation in the development of acute myelopathy following CAR T-cell therapy for diffuse large B-cell lymphoma. Current Research in Translational Medicine. 70(2). 103331–103331. 4 indexed citations
10.
Beauvais, David, Ibrahim Yakoub‐Agha, Suman Mitra, et al.. (2021). Effective anti-BCMA retreatment in multiple myeloma. Blood Advances. 5(15). 3016–3020. 27 indexed citations
11.
Beauvais, David, Séverine Loridant, Rémy Nyga, et al.. (2021). Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy. Journal of Microbiology Immunology and Infection. 54(2). 327–330. 7 indexed citations
12.
Beauvais, David, Isabelle Berthaut, Aurélie Cabannes‐Hamy, et al.. (2021). Semen Cryopreservation in Adolescents and Young Adults with Hematologic Diseases: from Bed to Benchside. Journal of Adolescent and Young Adult Oncology. 11(4). 389–393. 1 indexed citations
13.
Beauvais, David, Emmanuel Bachy, André Baruchel, et al.. (2021). Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC. Bulletin du Cancer. 108(7-8). 725–729. 2 indexed citations
14.
Giebel, Sebastian, Myriam Labopin, Gèrard Socié, et al.. (2020). Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation. 56(5). 1047–1055. 1 indexed citations
15.
Bocket, Laurence, David Beauvais, Pauline Varlet, et al.. (2020). A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel. Journal of Molecular Diagnostics. 23(4). 447–454. 6 indexed citations
16.
17.
18.
19.
20.
Grzych, Guillaume, et al.. (2018). Benefit of point of care testing in patient with major hyperleukocytosis. Clinical Biochemistry. 65. 55–57. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hamza Hashmi Breakdown of academic impact, for papers by Santiago Thibaud Breakdown of academic impact, for papers by Kirsten M Boughan Breakdown of academic impact, for papers by Odelia Amit Breakdown of academic impact, for papers by Caroline L. Furness Breakdown of academic impact, for papers by Tomoyasu Jo Breakdown of academic impact, for papers by Ben Carpenter Breakdown of academic impact, for papers by Rafic Farah Breakdown of academic impact, for papers by Agrima Mian Breakdown of academic impact, for papers by Alberto Mussetti
Rankless by CCL
2026